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During the past several years, there has been intense research in the ﬁeld of bone marrow-derived stem cell (BMSC) therapy to
facilitate its translation into clinical setting. Although a lot has been accomplished, plenty of challenges lie ahead. Furthermore,
there is a growing body of evidence showing that administration of BMSC-derived conditioned media (BMSC-CM) can
recapitulate the beneﬁcial eﬀects observed after stem cell therapy. BMSCs produce a wide range of cytokines and chemokines that
have, until now, shown extensive therapeutic potential. These paracrine mechanisms could be as diverse as stimulating receptor-
mediated survivalpathways,inducingstemcell hominganddiﬀerentiationorregulating theanti-inﬂammatoryeﬀects inwounded
areas. The current review reﬂects the rapid shift of interest from BMSC to BMSC-CM to alleviate many logistical and technical
issues regarding cell therapy and evaluates its future potential as an eﬀective regenerative therapy.
1.Introduction
The objective of stem cell regenerative therapy is to treat
damaged organ tissues by avoidingthe processes of cell death
and/or inadvertent remodeled Tissue [1]. Great optimism
has resulted from bone marrow derived stem cell (BMSC)
research ever since it showed to contribute signiﬁcantly to
the reestablishment of some functionality in injured organs
[2, 3]. The mechanisms by which stem cells function and
reverse the eﬀects of cell death include diﬀerentiation, cell
fusion, and secretion of cytokines or paracrine eﬀects [1, 4–
6]. More speciﬁcally, studies injecting BMSCs have shown
to improve functionality of ischemic tissue by promot-
ing neovascularization, inhibition of apoptosis and anti-
inﬂammation, better localization and homing of therapeutic
cells, and stimulation of endogenous cells diﬀerentiation
and proliferation [7–10]. Although a lot of research has
been focused on the ability of stem cells to diﬀerentiate
within the injured areas, more recent research suggests other
mechanisms may be more therapeutically relevant. It will be
argued that understanding paracrine mechanisms, mediated
by stem cells, is essential if stem cell regenerative therapy is
ever to reach clinical importance.
Indeed, understanding the therapeutic eﬀects of regener-
a t i v et h e r a p yu s i n gB M S C sb e c o m e sm o r er e l e v a n tw h e nw e
look at the paracrine factors, which are secreted by BMSCs.
For example, the frequency of stem cell engraftment and
the number of newly generated cardiomyocytes or vascular
cells are too insigniﬁcant to represent the remarkable
cardiac functional improvement attributed to fusion or2 Bone Marrow Research
diﬀerentiation alone [11]. In addition, in vivo transplanted
cells are exposed to local immune cells and soluble media-
tors, which inﬂuence the cells behavior in an unpredictable
manner in the microenvironment. Thus, it is necessary to
further understand the potential beneﬁts of maximizing
the paracrine eﬀects for regenerative therapy. This review
will take an in-depth look at speciﬁc mechanisms regulated
by these factors and potential therapeutic applications of
BMSC-CM and paracrine factors secreted by BMSCs.
BMSCs include many populations of progenitor cells:
hematopoietic stem cells (HSC), mesenchymal stem cells or
stromal cells (MSC), side population cells, and multipotent
adult progenitor cells [12]. BMSCs can be aspirated, and the
entire mononuclear cell fraction containing a heterogeneous
mix of progenitor and inﬂammatory cells is obtained
through density-gradient centrifugation using Ficoll. MSCs,
which are commonly used in the lab, are present at a
concentration several folds lower than their hematopoietic
counterparts, representing approximately 0.01% of the total
nucleated marrow cell population. They are separated from
other cells in culture by their preferential attachment to
plastic surfaces [13–16]. MSCs do not express hematopoietic
or endothelial cell surface markers. MSCs are expandable
in culture without losing their diﬀerentiation potential
and constitute an unlimited pool of transplantable cells.
They are multipotent and can diﬀerentiate into multi-
ple lineages, including ﬁbroblasts, osteoblasts, chondrob-
lasts, and adipocytes [17–23]. Diﬀerentiation of MSCs to
cardiomyocyte-like cells has been observed in vitro under
speciﬁc conditions and in vivo after injection into the
myocardium [24–27].
2.EmergingRoleof BMSCsforCelland
TissueRegenerationTherapy
MSCsareparticularlysuitableforcelltherapybecauseofeasy
isolation, high expansion potential giving unlimited pool of
transplantable cells, low immunogenicity, amenability to ex
vivo genetic modiﬁcation, and multipotency [24, 28, 29].
Although MSCs undergo lineage-speciﬁc diﬀerentiation to
generate bone, fat, and cartilage, they have been reported to
transdiﬀerentiate into deﬁned ectodermal and endodermal
tissues [30]. Furthermore, MSCs are available for autologous
therapies, can bypass immune rejection, and are inherently
migratory. Diﬀerentiation of MSCs into cells expressing
cardiomyocytes markers has been obtained in vitro and in
vivo [26, 27, 29, 31–36] .T h e ya r ea l s ok n o w nt os e c r e t ea
variety of biologically active factors and promote collateral
blood ﬂow development through paracrine mechanisms
[37–44]. Moreover, bone marrow stromal cells are capable
of diﬀerentiation, regeneration of infarcted myocardium,
induction of myogenesis, and promotion of angiogenesis.
These cells can potentially diﬀerentiate into cardiomyocytes
in vivo and even express functional adrenergic and mus-
carinic receptors [45, 46]. Moreover, conditioned medium
collected from MSC (MSC-CM) promotes in vitro prolifer-
ation and migration of endothelial cells and vascular smooth
muscle cells, and enhances blood ﬂow recovery of ischemic
hindlimb [37, 43, 44]. Following exposure to hypoxia and
serum starvation, MSCs are stimulated to secrete several
growth factors and cytokines[47]. Noiseux et al. have shown
that injection of MSC-CMeither directly into infarcted heart
by intramyocardial or intraperitoneal injections improve
myocardial function and repair [48–56]. The mechanism by
which MSCs may exhort beneﬁcial eﬀects is debated but is
certainly synergistic [57].
Although the mechanisms and the therapeutic beneﬁts
have not yet been fully elucidated, general consensus states
that adult stem cells, particularly BMSCs, are very safe.
This is based on their usage in human studies, which have
shown that they can be safely cultured in vivo with little risk
of malignant transformations [6]. Pitfalls to be considered
when working with MSCs are that transplantation of MSCs
alone can generate local immune responses and disrupt
homeostasis within tissue milieu by causing the release of
inﬂammatory mediators such as cytokines [32]. Moreover,
the therapeutic ability of BMSCs to suppress immune
responses may indirectly promote metastatic tumour pro-
liferation and growth. In addition, cytogenic abnormalities,
such as tumour diﬀerentiation, have been observed in
MSCs which have undergone extensive culturing and long-
term passaging [6]. Another area of concern involving
BMSCs was unveiled when a group recently discovered
that transplanted BMSCs in ischemic rat hearts led to
calciﬁcations/ossiﬁcations [58]. This latter group stresses the
importance of long-term studies, which will help determine
the provenance, multipotency, and long-term fate in vivo.
However, the same group discovered that use of cytokines
derived from the BMSCs did not lead to these pathological
malformations. Therefore, more data describing the long-
term eﬀects of administered MSCs and their factors are
needed to be established. In addition, since BMSCs can be
obtained directly from adult animal models, there are no
pressing ethical issues limiting their usage in clinical trials.
Although there are many beneﬁts attributed to MSCs, it
is important to know that the unique properties of MSCs do
not guarantee that they will accomplish desired therapeutic
outcomes or that they will evade rejection. This is the
reason for the various conﬂicting results with regards to the
mechanisms and outcomes of MSCs found in the literature.
Hence, current research is highly focused on developing an
eﬃcient delivery system that can successfully transplant a
suﬃcient number of stem cells at the desired site with higher
retention and minimal biological loss or immune response.
Some of our more recent work has shown that retention can
beincreasedbyfourfoldsintheheartbyusingbiocompatible
polymeric alginate microcapsules as a delivery system, which
can, in turn, help in functional recovery of acutely infarcted
heart [59–61].
3.ExploitingtheCellFusionand
DifferentiationPropertiesofBMSCs:
Potentialsand Limitations
Since heart disease is reaching pandemic proportions in
developed and developing countries and the heart is anBone Marrow Research 3
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Figure 1:Formationofintercellular connectionsafteroxygenglucosedeprivation.(a)Nanotubularnetworkformationwasobservedamong
DiO-labeled cardiomyoblasts(green) andDiD-labeled MSCs(red) after24hours ofcoculture. (b) MitoTrackerstaining(red) revealed active
mitochondria in the nanotubular networks [5].
organ of limited regenerative capacity, much research using
stem cell therapy is focused on the regeneration of the
myocardium. Therefore, studies focusing on stem cell dif-
ferentiation and cell fusion are often looking at the heart.
In earlier studies concerning cardiac regeneration, successful
transplantation of neonatal and fetal cardiomyocytes into
rats with acute myocardial infarction was observed [62]. The
results showed improved left ventricular function attributed
to the formation of stable intracardiac grafts [63–67]. The
implanted cells also retained their contractile phenotype
and expressed necessary elements for intercellular electrical
communication.
Oric et al. demonstrated that bone marrow could be
a source of extracardiac source of progenitor cells with
the ability to diﬀerentiate into cardiomyocytes and restore
cardiac function [9, 68, 69]. Since then, cardiogenic capa-
bilities have been conﬁrmed in hematapoietic stem cells,
MSCs, circulating endothelial progenitor cells, and resident
cardiac progenitor cells [11, 70–74]. Moreover, when the
BMSC are transplanted into ischemic heart, they express
the cardiac speciﬁc markers troponin I and cardiac myosin,
allowing researchers to easily identify the transformation
into functional cardiomyocytes and shows that histological
diﬀerence is indeed occurring [71, 75, 76].
Cell Fusion of transplanted stem cells with resident
cardiomyocytes has been proven as a feasible mechanism
for diﬀerentiation. Fusion of bone marrow-derived cells
with purkinje neurons, hepatocytes and cardiomyocytes was
reported for the ﬁrst time by Alvarez-Dolado et al. [77].
During cell, fusion the cells connect and exchange vital
cell components [4, 78]. Cseleny´ ak and others performed
an elaborate in vitro experiment suggesting the presence of
cellular nanotubes which increased the viability of ischemic
cardiomyoblasts in the presence of normal MSCs [5]. It
reveals that the viability of H9c2 rat cardiomyoblast cell
line depends on the nanotubular connection with rat
MSCs because when the nanotubes were blocked with cell
culture inserts, the H9c2 viability decreased signiﬁcantly.
Figure 1 s h o w sc a r d i o m y o c y t e sa n dh u m a nm e s e n c h y m a l
cells communicating through small diameter nanotubes,
which allow for the migration of organelles such as the
mitochondria from MSCs to cardiomyocytes. The graph
in Figure 2 illustrates the antiapoptotic eﬀect of MSCs on
stressed cardiomyocytes and how the nanotubular networks
are crucial to their eﬀects.
In a separate experiment, Noiseux et al. demonstrated,
using a model of acute MI in transgenic mice, that trans-
planted MSCs could fuse with recipient cardiomyocytes in
the infarcted area [79]. MSCs from wild-type C57BL/6 mice
wereretrovirally transducedtoexpressgreenﬂuorescentpro-
tein (GFP) (reporter gene) and Cre recombinase. These MSC
were transplanted into infarcted heart of histocompatible
R26R mice. In these transgenic mice, a loxP-ﬂanked stop
sequence was present 5  of the LacZ expression cassette to
prevent transcriptional read through until selective excision
byCre-mediatedrecombinationfromimplantedMSC.Thus,
the LacZ gene was expressed exclusively after a donor MSC
expressing Cre fused with a recipient cell from the R26R
mice. Consequently, X-gal staining is used to detect cellular
fusion events [77, 80]. This useful method, based on Cre/lox
recombination that conditionally turns on the LacZ gene
only in the fused cells, allows experimenters to rapidly
observe tissue sections covering a large area of the infarcted
and MSC-injected heart. The cells that were transplanted
were found within the infarcted myocardium (detection of
MSC by GFP immunoreactivity); early massive engraftment
was observed at 3 days, but the number of implanted MSC
decreased signiﬁcantly over time, and by day 28 post-MI
very few cells remained. As early as 3 days following MSC
injection into ischemic heart, they observed cellular fusion
with individual blue cells having typical cardiomyocytes
morphology. Interestingly, the majority of the fusion events
with LacZ+ cells were detected within the infarct border
zone, in areas with viable cardiomyocytes. Although cell4 Bone Marrow Research
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Figure 2: Cocultivation of cardiomyoblast (H9c2) cells with MSCs
decreased cell death in oxygen glucose-deprived environment.
(C): ratio of dead H9c2 cells after oxygen glucose deprivation.
(C+MSC): ratio of dead H9c2 cells after co-cultivation with MSCs
and under oxygen glucose deprivation (85 ± 8.6v e r s u s1 6± 3.5,
n = 5). (C+MSC ins): ratio of dead H9c2 cells when MSCs were
addedwithcellcultureinserts(90±5.5,n = 5).Datarepresentmean
± Standard deviation. ∗P<. 05 C+MSC versus C and C+MSC
versus C+MSC ins [5].
fusion was shown to occur by the appearance of blue
cells (fusion of MSC with resident cardiomyocytes) and by
the improved cardiac function, they concluded that fusion
was not responsible because it happened so infrequently.
Therefore, they attributed enhanced cardiac function to
paracrine eﬀects [79].
Despite hopeful results with experiments looking at
fusion and diﬀerentiation, the mechanisms by which BMSCs
work to help damaged tissue remains unclear even in seem-
ingly successful studies. Furthermore, inconsistent results
when researching stem cell regenerative capacity have been
linked to improper labeling of donor cells and inability
to consistently track them in vivo, making it very diﬃcult
to distinguish them from background tissue leading to
misinterpretation [81]. For example, the utilization of the
GFP reporter gene is attractive because it is compatible with
avariety ofimaging techniques;howeverdeadand dying car-
diomyocytes have an autoﬂuorescent spectrum that partially
overlaps with that of GFP. Therefore, after injury, autoﬂu-
orescence increases due to accumulated lipofuscin, blood-
derived pigments, and other intrinsic ﬂuors such as ﬂavins
and reduced nicotinamide adenine dinucleotide (NADH)
[82]. Evidence for regeneration includes colocalization of
GFP ﬂuorescence from donor cells, with immunostaining
for cardiomyocyte markers, including sarcomeric actin cells.
One major limitation of cell therapy is the low therapeutic
eﬃcacy of transdiﬀerentiated cells in the site of injury.
The low rate of sustained transplanted engrafted stem cells
has been attributed to cell stress, hostile environment due
to inﬂammation and hypoxia, insuﬃcient blood supply,
and elaboration of inﬂammatory cytokines resulting from
ischemia and cell death [83–86]. In addition, overdiploid
DNA fusion events between embryonic stem cells and
BMSCs can result in cell fusion with 2 nuclei (2n +2 n), or
alternatively nuclear fusion will result in cells with larger
nuclei 4n chromosomes going up to hexaploid (6n)D N A
content. This leads to hybrid genotypes with cells failing to
express proper green ﬂuorescent phenotypes adding to the
confusion of tracking diﬀerentiated cells [87].
4.Exploitingthe ParacrineFactors
Released from BMSCs
Since research has shown that stem cell diﬀerentiation and
fusion alone cannot account for enhanced cardiac function,
evidence for a nonmyogenic pathway of cardiac repair is
becoming increasingly explored. The debate surrounding
fusion and diﬀerentiation is of little importance now
because the number of reported cardiomyocytes derived
from exogenous stem cells is too low to account for the
impressive enhancement of physiological function [62, 88].
Thus, it has been proposed that stem cell transplantation
possesses therapeutic eﬀect because of the endogenous
repair mechanisms secreted by the BMSCs that account for
f u n c t i o n a lb e n e ﬁ t so fc e l lt h e r a p yi nc a s e ss u c ha sc a r d i a c
repair.
MSCs such as BMSCs are known to secrete many
biological factors, and under strenuous hypoxic and serum
starvation, the expression of several of these factors is
upregulated. This has prompted the isolation of MSC
conditioned medium (MSC-CM) to be concentrated and
used therapeutically. Kinnaird et al. reported the presence of
cytokines as: VEGF, FGF-2, IL-6, PIGF, and MCP-1 and that
intramyocardial injection of MSC-CM improved collateral
blood ﬂow recovery and limb function and reduced muscle
atrophy. Because all these cytokines are known to promote
angiogenesis and vascularization, the conclusion was that
it was not direct cell incorporation but rather paracrine
signaling that may be responsible for the eﬀects of bone
marrow cell therapy in ischemic injury.
It was previously reported that stem cell transplantation
into the ischemic myocardium improved cardiac function
recovery and repair as early as 72 hours later, which is too
early to be explained solely by MSC diﬀerentiation [55, 56,
79]. To see how the MSCs confer protection of the ischemic
myocardium through paracrine mediators and indirect
eﬀects, it was demonstrated that MSC-CM reduced hypoxia-
induced apoptosis and triggered spontaneous contraction of
isolated hypoxicadult rat cardiomyocytes in vitro, suggesting
the presence of antiapoptotic and inotropic eﬀects [55].
When injected directly into infarcted rat hearts, the MSC-
CM limited infarct size as early as 72 hours and improved
ventricular function at levels comparable to those observed
following MSC transplantation. From this data, it is clear
that the therapeutic eﬀects observed after intramyocardial
injection of MSC in the infarcted hearts are, at least, in
part attributable to the paracrine eﬀects on the ischemic
myocardium. Paracrine factors can also play an important
role in inﬂuencing the adjacent cells and exert their actions
via diverse mechanisms. Furthermore, it is likely that the
paracrine mediators are expressed in a speciﬁc temporal
and spatial manner that can enhance cell survival and
activate endogenous mechanisms of endogenous repair and
regeneration [11]. Figure 3 provides a simplistic overview
of the observed therapeutic potentials that arise fromBone Marrow Research 5
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Figure 3: Schematicrepresentation of thehypotheses presenting therapeutic eﬀects ofstemcell transplantationformyocardialregeneration.
Cell transplantation can improve tissue perfusion and contractile performance by promoting formation of blood vessels and myocyte
formation/protection.Centralto thebeneﬁcialeﬀects ofcellulartherapyistheparacrineandindirect eﬀects ofstemcells withtheproduction
and release ofcytokines and growth factors. Depending on the stem cell type and local milieu,the relative contribution of cell incorporation
(transdiﬀerentiation and/or fusion) versus paracrine eﬀects may vary [27].
BMSC cardiovascular therapy and illustrates the direct and
indirect inﬂuences of paracrine factors on overall cardiac
functionality. Furthermore, Table 1 gives a brief overview of
speciﬁc identiﬁed factors secreted by human MSCs detected
by protein array [52].
4.1. Paracrine-Mediated Neovascularization. Blood vessel
formation after birth proceeds primarily through 2 mech-
anisms: angiogenesis and arteriogenesis. Angiogenesis con-
sists of several distinct processes which include sprouting
and proliferation of pre-existing capillaries to form new
networks. This process is tightly regulated by hypoxia
throughanumber of proangiogenic factors, includingVEGF,
FGFs, P1GF, and hepatocyte growth factor (HGF) [89–94].
The rapid proliferation of pre-existing collateral arteries
characterized by arteriogenesis involves remodeling small
arterioles into larger vessels and is triggered in part by
an increase in stress in arterioles that run parallel to the
occludedartery. Recruitment of monocytes that diﬀerentiate
into macrophages and produce abundant angiogenic growth
factors such as VEGF, NO, MCP-1, and other cytokines,
is also essential and ultimately leads to endothelial and
smooth muscle proliferation, migration, vessel remodeling,
and extracellular matrix synthesis [44, 94]. Arteriogenesis
is the most eﬃcient adaptive mechanism for the survival
of ischemic organs because of its unique capability to con-
duct large blood ﬂow. Angiogenesis and arteriogenesis are
complex processes sharing common mechanisms of action,
growth factors, and cytokine dependency. Furthermore,
these cytokines act not only in a coordinated time and
concentration-dependent manner, but one cytokine may
inhibit or stimulate the eﬀect of another. The complexity of6 Bone Marrow Research
Table 1: Detection of secreted factors from human mesenchymal cells under normoxic and hypoxic conditions. Relative concentration
between normoxic and hypoxic conditions are expressed from 1–5 with 1 being the lowest concentration and 5 being the highest [52].
Secreted factors Normoxia Hypoxia Biologicalfunction
Activin A 3 2 Cell proliferation, diﬀerentiation, apoptosis, and immune response
Epiregulin 33 R e m o d e l i n g
Endothelin 4 4 Cytoprotection, cell proliferation
Glypican-3 3 3 Cell proliferation
IGFBP-7 4 5 Cytoprotection, cell migration,and contractility
IL-15 alpha 2 1 Immune response
LRP-1 21 C e l l m i g r a t i o n
LRP-6 41 C e l l m i g r a t i o n
Osteoprotegrin 4 5 Bone development
sFRP-4 34 D e v e l o p m e n t , a p o p t o s i s
Smad4 3 2 Vessel maturation,cell proliferation
Smad7 2 2 Vessel maturation,cell proliferation
Thrombospondin-1 3 5 Cell migration,apoptosis
TIMP-1 4 5 Cell migration,remodeling
TIMP-2 4 5 Cell migration,remodeling
VEGF 3 4 Cytoprotection, proliferation, migration,and angiogenesis
the process of collateral formation has led to the suggestion
that multifactorial strategies will be necessary to modulate
therapeutic paracrine eﬀects including vessel formation.
Under normal circumstances, myocardial tissue dies and
forms scar tissue because the capillary network does not
meet the demands of the hypertrophied cells. The inevitable
lack of oxygen and nutrients leads to apoptosis and necrosis.
Moreover, inducing angiogenesis requires the coordinated
interactions between monocytes/macrophages, endothelial
cells, smooth muscle cells, and pericytes[92, 94–99]. Human
bone marrow-derived multipotent stem cells allow for
angiogenesisbyexpressingvariousangiogeniccytokinessuch
a sV E G F ,A n g - 1 ,A n g - 2 ,b F G f ,H G F ,a n dP D G F - B .M o r e
importantly, HGF, VEGF, bFGF, and IGF are known survival
factors that are expressed by cardiomyocytes [96, 97]. These
p a r a c r i n ef a c t o r sa r eb e l i e v e dt oi n ﬂ u e n c ea d j a c e n tc e l l s
via mechanisms including myocardial protection, neovas-
cularization, and most the activation of resident cardiac
stem cells and/or stimulation of endogenous cardiomyocyte
replication.
MSCs express genes encoding a broad spectrum of
cytokines with angiogenic properties of some of which may
be referred to in Table 1 such as VEGF, HGF, FGF, MCP-
1, PGF, IL-1 and IL-6, SDF-1, and MMP-9 [37, 44, 47].
All of these cytokines can be isolated from the media of
cultured cells and have all shown to have positive eﬀects
on experimental blood ﬂow recovery [37, 91]. In addition,
MSC-CM promotes in vitro proliferation and migration
of endothelial cells and vascular smooth muscle cells and
enhancesin vivo collateral bloodﬂow recovery when injected
into ischemic hindlimb. Another possibility for improved
functionisthatneovascularization bythestemcellsisleading
to enhanced blood supply in the peri-infarct region, thereby
promoting salvage of stunned, hibernating, or otherwise
susceptible cardiomyocytes [62].
4.2.Paracrine-Mediated Cell Homing/Targeting. Homing sig-
nals are extremely important for the eﬃcacy of cell therapy
b e c a u s ei ti sv i at h e s ep a r a c r i n ee ﬀects that the precise
localization of transplanted cells is possible and can be
improved. In the case of cardiac repair, stem cell therapy
can be administered via intravenous, intracoronary, trans-
myocardial, catheter-based transendocardial with or without
electromechanical voltage mapping, and ﬁnally transvenous
injection into coronary veins [100–104]. The goal of any
cell delivery strategy is to transplant enough cells into the
area of interest to achieve maximum retention in that area.
Moreover, the local environment determines the success of
cell delivery since it is the milieu that will inﬂuence short-
term cell survival, cell properties in regard to adhesion,
transmigration through vasculature, and tissue invasion.
Therefore, the targeted administration of cells is preferred
[105]. Cell homing, transmigration, adhesion, and tissue
invasion are the result of many complex steps. For example,
stromal-derivedfactor-1(SDF-1)isexpressedintheischemic
myocardium and plays an important role in endogenous
stem cell migration, adhesion, homing, and recruitment
from bone marrow. SDF-1 is an important chemoattractant
for progenitor cells and thus plays a crucial role in directing
cells into areas of infarcted myocardium [75]. Tang and
colleagues administered SDF-1 expressing plasmid into
ischemic borderzonesofmurine modelsinjected with BMCs
(Lin−c-kit+)[ 106] .As i g n i ﬁ c a n ta m o u n to ft h el a b e l e ds t e m
cells were found in the area where the plasmid was injected.
Thus, administering homologous cytokines is one way to
encourage the proliferation of injected stem cells.
Of all techniques, the intracoronary infusion has been
deemed best for treatment of acute myocardial infarction.
However, strategies to augment cell function via better
localization/homing iscrucialifthereistobeany therapeutic
beneﬁt using BMSCs for targeted regenerative therapy.Bone Marrow Research 7
Additional strategies for better homing of mesenchymal cells
include inducing hypoxia for the upregulation of CXCR-
4 protein receptor expression at the BMSC cell surface.
CXCR-4 are chemokine protein receptors expressed in dying
cells, which can be complexed with SDF-1 protein ligands
[107, 108]. The CXCR-4/SDF-1 complex allows for stem cell
migration via chemotaxis where expression of the CXCR-4
receptor and the presence of SDF-1 receptor are required to
regulate and make cell migration possible. It has been found
that CXCR-4 expression can be induced by exposure to a
pool of cytokines such as SCF, IL-6, Flt- ligand, HGF, and
I L - 3 .F u r t h e r m o r e ,i n c r e a s i n ga ﬃnity of the stem cells can
also be done by increasing the concentration of the chemo-
attractant SDF-1. Therefore, a depot of angiogenic cytokines
and an increase in SDF-1 ligand can possibly be localized in
an area, allowing for eﬃcient stem cell homing [109].
Orlic et al. reported that injection of BMCs (Lin−c-kit+)
w a sa b l et og i v er i s et on e wm y o c a r d i u ma n di m p r o v el e f t
ventricle end diastolic pressure by 30% to 40% in mouse
hearts with infarcts located in the free wall of the left
ventricle [1, 110]. In a separate but similar experiment,
injections of the BMSC cytokines stem cell factor (SCF) and
granulocyte-colony stimulating factor (G-CSF) increased
numbers of circulating HSCs to a level 250-fold greater than
untreated myocardium. However, it is not clear whether
tissue repair is a result of the homing of BMC to the
lesion or if BMC, once mobilized, cells spreads through
the organism and only those exposed to damaged tissue
are triggered to proliferate and diﬀerentiate at a faster rate
than the others [9]. Nonetheless, the former hypothesis is
supported because of the rapid induction of SCF in many
tissues including the myocardium. Therefore, SCF could be
responsible for migration, accumulation, and multiplication
of primitive BMCs in the infarcted zone where they acquire
the appropriate phenotype.
4.3. Paracrine-Mediated Anti-Inﬂammatory Eﬀects. MSCs
are known for having potent anti-inﬂammatory activities,
which are present regardless of their tissue of origin. They
are said to suppress inﬂammation through secretion of
anti-inﬂammatory cytokines such as IL-10, TGF-beta,
LIF, soluble HLA-G, and IL-1 receptor antagonists [111].
The successful eﬀects of MSC have been demonstrated in
vivo and have treated animal models in cases of immune
mediate/inﬂammatory pathologies such as MS, colitis,
graft versus host, rheumoid arthritis, and ischemic injury
[112]. Most recently, Chen et al. have shown that MSCs
implantation after myocardial infarction in a rat model
caused a signiﬁcant upregulation of anti-inﬂammatory
versus the proinﬂammatory cytokines compared with
the control group without cell therapy [113]. It is
therefore conceivable that MSC factors can also work
by downregulating the genes, which promote inﬂammation
and therefore are useful against heart failure by suppressing
ongoing self-perpetuating inﬂammatory cascades.
As it has been aforementioned, knowing the microen-
vironment prior to cell transplantation or conditioned
media transplantation is crucial to avoid any immune-
mediated rejection. That being said, inclusion of speciﬁc
cytokine receptor antagonists or inhibitors can prevent the
immune-mediated responses of the host microenvironment
on transplanted cells. Since IL-1α/β,T N F - α, and SDF-1-α
are ubiquitousin thecell microenvironment, we must review
their mechanisms. First of all, these are pro-inﬂammatory
mediators, which are primarily synthesized by macrophages,
monocytes, and dendritic cells, and are responsible for
immune defense against inf e c t i o ni nm o s tt i s s u e s[ 114].
Greco and Rameshwar have shown that MSCs express IL-
1RI, which is the principal receptor for IL-1α and IL-1β
[32]. The researchers found that membrane expression of
the receptor was maintained throughout transdiﬀerentia-
tion of MSCs into neurons. Moreover, IL-1α was found
to alter behavior of undiﬀerentiated MSCs. Stimulation
of MSCs with IL-1α caused production of substance P
neurotransmitter by undiﬀerentiated and diﬀerentiatedcells.
Excessive production of substance P neurotransmitter leads
to exacerbated immune responses and untoward eﬀect on
MSC diﬀerentiation. On the other hand, delivering MSCs
together with inﬂammatory cytokine antagonist/inhibitor
may suppress immunoreactivity allowing for the expected
therapeutic result [115]. Therefore, knowing the correct
inhibitors will assure optimal functioning of transplanted
cells or media.
As demonstrated in vitro and in vivo, it is now known
that BMSCs can be immunosuppressive and escape cyto-
toxic lymphocytes [116, 117]. One mechanism by which
immunosuppressive eﬀects are mediated is by Fas-mediated
apoptosis. Cells expressing FasL speciﬁcally protect against
T-cell-mediated cytotoxicity where T cells expressing Fas are
sensitive to Fas-mediated apoptosis. One study hypothesized
that this immunosuppressive action is mediated by FasL-
inducedkilling ofactivated lymphocytes,thereby, preventing
lymphocyte attack. It has been suggested that cell engraft-
ment can be improved by the pretreatment of cells with anti-
apoptotic or “cytoprotective” genes; some of which can be
found in stem cell media (Akt, Bcl2 GSK, IlK, telomerase,
and eNOS) [118].
4.4. Paracrine-Mediated Endogenous Cell Stimulation. Acti-
vating speciﬁc cells through paracrine/endogenous eﬀects
of growth factors released by BMSC is showing promise.
The kidney, similar to the heart, has a limited regenerative
capacity.However,recentstudieshavesuggestedthepresence
of stem cell renal niches, that is, renal papillae in animals
and in the urinary pole of Bowman’s capsule in humans.
The importance of these CD24+ and CD133+ stem cells
during kidney damage has not yet been elucidated, and
it has been found that MSCs contribute to renal repair
[119]. Similarly to cardiac treatments, when treating the
kidney with transplanted MSCs, several studies documented
renalrecoverywithoutdiﬀerentiationofMSCsintoepithelial
cells. Therefore, it was also suggested that cell migra-
tion facilitated regeneration because of endocrine/paracrine
eﬀects and that it was the kidney stem cells that were re-
generating the tubular epithelium [120–125]. Furthermore,
the body also possesses local source of cardiac stem cells,8 Bone Marrow Research
which can diﬀerentiate into myocytes and possess growth
factor-receptor systems allowing for the regeneration of
infarcted myocardium. It is known that HSCs and MSCs
can stimulate activation of these cardiac resident stem cells
because they can produce HGF and IGF-1 which are not
only anti-apoptotic but can activate endogenous stem cells
[126]. Interestingly, these factors are upregulated in response
to inﬂammatory mediators such as TNF-alpha. Therefore,
when responding to inﬂammatory stimuli, MSCs and HSCs
can, in addition, potentially recruit endogenous stem cells
[109].
5.RecentApplicationsof
StemCell-ConditionedMedia in
the BiomedicalFields
5.1. Cardiac Regeneration. Although this is a novel topic,
some studies have been done using BMSC-derived con-
ditioned media (BMSC-CM). Their preliminary results
suggested that much more eﬀorts should go into further
researching the beneﬁts of conditioned media to better
understand the role of individual factors that may opti-
mize their eﬀects. Interest in this topic started when
researchersreportedfunctionalimprovementoftissuebefore
the possibility of attributing it to donor cells. Gnecchi
and colleagues found signiﬁcant functional improvement
in the myocardium occurring in less than 72 hours after
intramyocardial injection of Akt-modiﬁed MSCs in a rat
model [56] .T h es a m eg r o u pl a t e ro b s e r v e dt h a tc e l lf u s i o n
events were occurring and were associated with better
cardiac performance. However, the cell fusion and diﬀeren-
tiation events were so uncommon that they attributed the
enhanced cardiac function to paracrine factors expressed
by MSCs [48, 79]. Nguyen et al. are the ﬁrst to research
the eﬀects of MSC-CM on the myocardium [52]. After
subjecting swine to acute MI by balloon occlusion of
the left anterior descending coronary artery, the eﬀects
of intracoronary injections of either concentrated MSC-
derived growth factors or control medium were observed.
MSC-derived factors signiﬁcantly reduced serum cardiac
troponin T (cTnT) that has been validated as a biomarker
that increases with the severity of injury. The treatment
group also showed signiﬁcant echocardiographic functional
improvement. Staining analysis also revealed a reduction
of the ﬁbrotic area in the infarct zone and increment
of preserved area in the infarcted myocardium. This was
associated withless apoptosis ofcardiomyocytes.The rolesof
angiogenic (vascular endothelial growth factor, endothelin,
and epiregulin), anti-apoptotic( G a l e c t i n - 3 ,S m a d - 5 ,s R F P -
1, and sRFP-4) and anti-remodeling factors have all been
detected by protein array in the control group.
Recent research has also shown that there is an optimal
time for conditioned media delivery since the paracrine
eﬀects are known to be time dependent. It has been
demonstrated that the prohypertrophic eﬀects on myocytes
and proliferation of ﬁbroblasts in rat myocardium were
signiﬁcant using media collected after 6 and 9 hours of
secretion. On the other hand, medium collected at 3 and
24 hours after secretion resulted in no noticeable prohy-
pertrophic eﬀects. Consequently, the presence of FGF-2, IL-
1, IL-6, TGF-β and TNF-α factors during these optimal
times suggests that they all take part in hypertrophy and
proliferation of the cardiomyocytes [127].
5.2. Renal Regeneration. Similarly to stem cell therapy in
myocardial regeneration, studies in the kidney provided
no evidence that marrow stromal cells were incorporating
into the native renal parenchyma in signiﬁcant numbers or
directly contributed to tubular cell repopulation [120]. Bi
and colleagues studied whether BMSC-CM injections had
any beneﬁcial eﬀects on the renal system. Using in vitro
mouse proximal tube cells (MPT) cultured (24 hours) with
cisplatin with and without BMSC-CM, they showed that
sustained exposure to toxic cisplatin resulted in detachment
and death of many MPTs. The presence of BMSC-CM, how-
ever,signiﬁcantlyinhibitedcelldetachmentandinhibitedcell
deathafter48h.Thesamestudyinvestigatedthemechanisms
of renal repair after BMSCs injection. They showed no
evidence of renal cell regeneration but rather the endocrine
eﬀects conferred the greatest therapeutic beneﬁt for the cells
[125].
5.3. Neurotrophic Actions of BMSC-CM. Bone marrow stro-
mal cells also showed great potential with regards to
neurological regenerative therapy. BMSCs have shown to
contribute to functional recovery and tissue regeneration
in rat models with spinal cord injury, cerebral ischemia,
traumatic brain injury, and constructing tissue-engineered
nerve grafts [128–130]. Researchers have investigated the
paracrine factorsreleasedbyBMSC-CMusingratdorsalroot
ganglion cells. They cocultured BMSC-CM with explants
or neurons, and cell proliferation assays showed that neu-
rite outgrowth and neuronal cell survival were enhanced.
Because they used transwell inserts and BMSC-CM, the cell
behaviors of explants and neurons were induced by soluble
factors released by BMSCs into the culture medium. The
factors contributing to immune cell migration to injury
site, remodeling, and cellular action which all contribute
to repairing injured nerves can be attributed to the factors
exerting paracrine factors such as 43 secretory proteins,
adhesion molecules, cytokines, and growth factors. Fur-
thermore proteomic analysis and ELISA further found that
BMSC-derived soluble factors were involved in activation of
PI3-K/Akt and MAPK signaling pathways in DRG neurons.
The activation of PI3-K/Akt and MAPK/Erk1/2 pathways
is crucial for survival signaling. Therefore, these results
suggested a new pathway by which cell survival might be
attributed to endocrine paracrine mechanisms [131].
6. FutureDirections
6.1. Advanced Cell Isolation Methods for Enhancement
of Paracrine Activities. Optimizing and maximizing the
amount of secreted stem cell paracrine factors is impor-
tant to assure its eﬃcient transition in therapeutic and
clinical applications. Preparation and isolation of MSC hasBone Marrow Research 9
traditionally involved plastic adherence isolation. Another
method for cell isolation is by immunoselection using
mesenchymal precursor cells (MPC) at higher purity. MSC
involving plastic adherence (PA) isolation has been shown
to be less eﬀective than MPCs immunoselected for stromal
precursor antigen-1 (STRO-1) [132, 133]. Thus STRO-1-
MPC displayed greater clonogenecity, proliferative capacity,
multilineage diﬀerentiation potential, and mRNA expres-
sion of mesenchymal stem cell related transcripts. As a
result, STRO-1-MPC exhibited higher gene and protein
expression and thus greater paracrine activity than PA-
MSC in vivo. More importantly, enrichment for STRO-1
increases the expression of cardiovascular-relevant cytokines
and enhanced trophicactivity. STRO-1-MPC,for example, it
exhibited higher expression of CXCL12 and HGF, which are
crucial in endothelial tube formation and cardiac cell pro-
liferation. Therefore, immunoselection has great potential in
the ﬁeld of regenerative therapy.
6.2. Nanobiotechnological Applications. Enhancing eﬀective-
ness of paracrine activity has also been attempted using
heparin-binding amphiphile nanoparticles (HBPA) [134].
Hypoxic-conditioned medium was derived from MSCs
which ledtosigniﬁcantly betterhaemodynamic performance
at 30 days after infarct in a mouse ischaemia-reperfusion
model of acute myocardial infarction. Interestingly, enough
MSC-CM-HBPA animals did not vary signiﬁcantly from
healthy animals with respect to LV contractility; thus,
HBPA nanoﬁbre networks resulted in signiﬁcantly greater
myocardialfunctionalperformancethanwithHBPAaloneor
with conditioned medium alone. The mechanism by which
the synergistic eﬀects of CM and HBPA functioned was
likely due to the heparin-containing nanoﬁbre gel concen-
trating heparin-binding factors, stabilizing factor-receptor
complexes, prolonging factor activity by suppressive prote-
olysis, and increasing retention through the introduction of
molecularaggregates ratherthan isolatedproteins. The study
also showed that loading HBPA nanoﬁbre networks with
nanogram quantities of growth factors VEGF and bFGF was
enough to recreate the enhanced cardiac function. However
the mechanism by which cardiac function was improved was
not well described especially because they did not notice
any changes relating to angiogenic factors. Therefore, they
postulated that the HBPA nanoﬁbre in synergy with the
conditioned media augmented function via trophic eﬀects
which has been shown to augment function by modulation
of cardiac metabolism. In other words, this new idea
proposes that paracrine factors might help erase ischemic
memory and help the heart utilize the cardiometabolic
reserves [135].
7.Conclusion
So far, bone marrow-derived stem cells and their paracrine
factors have shown all the necessary attributes for tissue
regeneration, namely, homing, immunosuppression, diﬀer-
entiation, angiogenesis, stimulation of endogenous cells,
and possible regulation of speciﬁc metabolic pathways, only
to name a few. Thus, research into paracrine factors and
mechanisms has shown that stem cell therapy is much
more complicated and greatly enhances the potential and
variety of therapeutic applications. Mediating angiogenic
factors, cell proliferation, and all of the above-mentioned
characteristics are crucial to stem cell therapy and provides
many newapproachesfortherapy.Therefore,injectingMSCs
into tissue and observing the extent of diﬀerentiation are to
be considered superﬂuous unless, of course, paracrine eﬀects
are being considered. Results from experiments using only
conditioned medium showed signs of remarkable promise
and revealedthesame regenerativecapacitiesasstudiesusing
cell injection. However the hallmarks of transdiﬀerentiation
and cell fusion are not to be disregarded because paracrine
activities will mostlikelymakethese processesmoreeﬃcient.
Therefore, research into using conditioned media from stem
cells is crucial because it will give us a greater understanding
into the most relevant and important cytokines, their
optimization, and their mechanisms of action to further
maximize the application and uses of regenerative stem cell
therapy.
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